Still here, still believe in this molecule and our
Post# of 148072
I'm in it for the long haul *wink wink*.
I find the seemingly quick enrollment of the longhaulers trial reassuring; as frustrating as Phase III may have seemed, the fact that we're still clear to continue trials should speak volumes about what this molecule is capable of.
We know much more about COVID than we did last year, and I believe trial design going forward will more clearly show the efficacy of Leronlimab.
As a shareholder I feel all that's required is patience, though that is difficult given how many lives could be saved over the next few months were we already approved.
All IMO